Changes in satiety hormones and safety in the use of tamarind-purified trypsin inhibitor with anti-inflammatory potential in an experimental model of obesity
obesity, CCK; leptin; Tamarindus indica; anti-inflammatory; toxicity.
Obesity is a multifactorial disease, difficult to manage and that increases the risk of other diseases. In the search for adjuvants in classical lifestyle change therapy, travel inhibitors are prominent. The experimental models of obesity aim to mimic a highly unbalanced dietary pattern. To understand how this pattern changes the hormonal balance that regulates energy metabolism, it evaluates the effect of a diet with a high index and glycemic load (HGLI) without body weight, cholecystokinin (CCK) and plasma leptin and with expression of its genes in the small intestine , brain stem and visceral fat. Male Wistar rats (n = 10) were divided into two groups, receiving a HGLI diet and another standard diet, both ad libitum, for 17 weeks. The animals that received HGLI diet increased the Body Mass Index (BMI) and as circulating leptin and its genetic expression. There was no increase in plasma CCK, but the group that received the HGLI diet showed greater expression of CCK1R mRNA in the small intestine. The results suggested for leptin to stimulate the expression of the CCK1R gene, increase the plasma increase in CCK, generate a synergistic action induced by the receptor, which can cause postprandial satiety. To understand how travel inhibitors can help treat obesity, perform a systematic review. Twelve studies were found that involved the performance of travel inhibitors in satiety in experimental models, whose main mechanism of convergent action for modulation, mainly CCK. In addition, travel inhibitors can act on biochemical parameters related to obesity, emerging as promising molecules. Tamarindo's Trypsin Inhibitor has been extensively studied in the obesity model, showing several fronts of action, both in its isolated (TTI) and purified (TTIp) states. TTI has already been analyzed from a toxicological point of view. Thus, in this study studied or in the TTIp for toxic effects, with involvement in the organs involved in its metabolism (liver and pancreas) and in the tissues most affected by the obesity model (intestine and visceral adipose tissue). For this, Wistar rats (n = 15) were divided into control groups, fed a standard diet; obese group, eating a HGLI diet; experimental group, fed with HGLI and treated with TTIp. The treatment lasted 10 days. Histopathological and stereological analyzes of tissues were performed. Note that the administration of TTIp does not affect the stereological parameters of the analyzed tissues, also acting as a protective factor of the intestinal mucosa. This finding leads one to believe that the TTIp, in addition to its biological activities, is safe in terms of use.